Cervical pathology: scope of gynecologist competence

Authors

  • В. М. Запорожан Odessa National Medical University, Ukraine
  • Т. Ф. Татарчук Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • В. Г. Дубинина Odessa National Medical University, Ukraine
  • Н. А. Володько Lviv National Medical University named after Danilo Galitskiy, Ukraine
  • Н. К. Силина Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2013.12.7-17

Keywords:

cervix, cervical cancer, human papillomavirus, cervical screening

Abstract

Cervical cancer in Ukraine is the leading cause of death among women of reproductive age. Every day in our country one in six women dies from cervical cancer.
Therefore, obstetrician-gynecologist and family doctor have the task of organizing the prevention of invasive cervical cancer. Screening signifi cantly reduces the timely cases and deaths from cervical cancer. Human papillomavirus (HPV) is the main cause of cervical cancer. At present, vaccination against HPV is considered to be a breakthrough in cervical cancer prevention in the XXI century.

Author Biographies

В. М. Запорожан, Odessa National Medical University

MD, Professor, Academician of Academy of Medical Sciences of Ukraine, Rector, Head of the Obstetrics and Gynaecology Department № 1

Т. Ф. Татарчук, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, professor, corresponding member of NAMS of Ukraine, Deputy Director for Research Work, Chief of the Endocrine Gynecology Department

В. Г. Дубинина, Odessa National Medical University

MD, professor, Head of the Oncology, Vice Rector of the medical work

Н. А. Володько, Lviv National Medical University named after Danilo Galitskiy

PhD, associated professor of the Oncology and Medical Radiology Department

Н. К. Силина, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

PhD, Senior Researcher at the Department of Medical and Psychosocial Family Problems

References

  1. Vorobyova LI Cervical cancer: ways to improve the diagnosis and treatment // Health of Ukraine. – 2009. – № 1/1. – P. 15.
  2. Zakhartseva LM, Pekur EA Frequency of p16INK4a protein expression and the presence of HPV in cervical dysplasia // Oncology. – Vol. 51, № 1. – 2013. – P. 9-13.
  3. Tatarchuk TF, Tutchenko TN Cervical pathology: goals for gynecologist // Reproductive Endocrinology. – 2013. – № 1 (9). – P. 39.
  4. American Cancer Society Guideline for HPV VacЦИНe Use to Prevent Cervical Cancer and Its Precursors.CA Cancer J Clin 2007;57:7–28.
  5. ASC-US-LSIL Triage Study (ALTS) Group. A random- ized trial on the management of low-grade squamous intra- epithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393Y400.
  6. Bornstein J, Bentley J, Bosze P, Girardi F, Haefner H, Menton M, Perrotta M, Prendiville W, Russell P, Sideri M, Strander B, Torne A, Walker P 2011 IFCPC colposcopic nomenclature.
  7. Diane Cooper, Margaret Hoff man, Henri Carrara Determinants of sexual activity and its relation to cervical cancer risk among South African Women.
  8. Katki HA, Schiff man M, Castle PE, Fetterman B, Poitras NE, Lorey T et al. Five-Year Risk of ЦИН 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results. J Low Genit Tract Dis 2013;17:S36YS42.
  9. Katki HA, Gage JC, Schiff man M, Castle PE, Fetterman B, Poitras NE et al. Follow-up Testing After Col- poscopy: Five-Year Risk of ЦИН 2+ After a Colposcopic Diagnosis of ЦИН 1 or Less. J Low Genit Tract Dis 2013;5:S69YS77.
  10. Moberg M, Gustavsson I High viral loads of human papillomavirus predict risk of invasive cervical carЦИНoma. British Journal of Cancer 2005, March 14; 92(5) 891-894.
  11. Moody CA, Laimins LA Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010 Aug;10 (8):550-60. Epub 2010 Jul 1.
  12. Moscicki AB, Shiboski S, Hills NK et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678–1683.
  13. Rodrigues AC et al. JNCI 2009;101:721- . Chen HC et al. JNCI2011;103:1387-96.
  14. Sawaya GF et al.Acta Cytol 2005; 49: 391-7.
  15. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiff man M, Castle PE Myers ER, ACS-ASCCP-ASCP Cervical Cancer Guidelines Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May;62(3):147-72.
  16. Wael I Al-Daraji, John HF Smith Infection and Cervical Neoplasia: Facts and Fiction. Int. Journal of clinical and experimental pathology. 2009.- №2(1).- C.48-64.
  17. Zereu M, Zettler CG, Cambruzzi E, Zelmanowicz A Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarЦИНoma of the uterine cervix. Gynecol Oncol. 2007 Apr;105(1):172-5.
  18. http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-risk-factors.
  19. http://www.ncbi.nlm.nih.gov/pubmed/22752992.
  20. Keith Wing-Kit Lo, Sze-Wan Yeung,Tak-Hong Cheung et al.Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: A study in Chinese population. Journal of Clinical Virology 34 (2005) 76–80.

Published

2013-08-17

How to Cite

Запорожан, В. М., Татарчук, Т. Ф., Дубинина, В. Г., Володько, Н. А., & Силина, Н. К. (2013). Cervical pathology: scope of gynecologist competence. REPRODUCTIVE ENDOCRINOLOGY, (12), 7–17. https://doi.org/10.18370/2309-4117.2013.12.7-17

Issue

Section

Analytical review